HC Wainwright Reiterates Buy Rating for Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued to investors on Monday, November 6th. They presently have a $19.50 price target on the stock.

Other research analysts have also recently issued research reports about the company. ValuEngine upgraded Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 2nd. Ifs Securities reissued an “outperform” rating on shares of Rexahn Pharmaceuticals in a research report on Monday, August 7th. Zacks Investment Research raised Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Wednesday, October 4th. Finally, Seaport Global Securities restated a “buy” rating and issued a $13.00 price objective on shares of Rexahn Pharmaceuticals in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Rexahn Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $13.65.

Rexahn Pharmaceuticals (RNN) traded up $0.19 during mid-day trading on Monday, hitting $2.32. The stock had a trading volume of 860,272 shares, compared to its average volume of 712,123. Rexahn Pharmaceuticals has a 1-year low of $0.38 and a 1-year high of $7.10.

A number of hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Rexahn Pharmaceuticals during the 3rd quarter worth about $119,000. Sabby Management LLC bought a new stake in Rexahn Pharmaceuticals during the 2nd quarter valued at approximately $706,000. Susquehanna International Group LLP bought a new stake in Rexahn Pharmaceuticals during the 2nd quarter valued at approximately $2,905,000. Finally, Renaissance Technologies LLC boosted its stake in Rexahn Pharmaceuticals by 17.6% during the 1st quarter. Renaissance Technologies LLC now owns 5,758,391 shares of the company’s stock valued at $2,937,000 after purchasing an additional 862,000 shares during the period.

TRADEMARK VIOLATION NOTICE: This article was first reported by BBNS and is the property of of BBNS. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://baseballnewssource.com/markets/rexahn-pharmaceuticals-inc-rnn-receives-buy-rating-from-hc-wainwright/1762081.html.

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Analyst Recommendations for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan


Leave a Reply

 
© 2006-2017 BBNS.